基于对接和分子动力学模拟的高级小分子激酶抑制剂的分析 确定了前-let-7 miRNA 结合剂
Soma Roy1,2, Yang Liu1,2,3, Peng Wu1,2,3
1Chemical Genomics Centre, Max Planck Institute of Molecular Physiology, Otto-Hahn Str. 11, 44227, Dortmund, Germany.
Chembiochem : a European journal of chemical biology
|July 9, 2025
概括
这项研究选了78种FDA批准的小分子激酶抑制剂 (SMKI) 与前微RNA let-7结合. 几种SMKI显示出有希望的结合亲和力,这表明了潜在的针对疾病的RNA向治疗策略.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 异常的RNA表达和错误折叠导致各种疾病,包括由microRNA过度表达驱动的癌症.
- 用小分子向与疾病相关的microRNA是一种新兴的治疗方法.
- 小分子激酶抑制剂 (SMKI) 是先进的治疗方法,但它们与RNA标的相互作用尚未得到充分研究.
研究的目的:
- 调查78个FDA批准的SMKI与pre-let-7微RNA的结合亲和力.
- 探索SMKI作为RNA向剂的潜力.
- 描述SMKI和RNA之间的绑定环境.
主要方法:
- 使用对接,对78个FDA批准的SMKI进行了计算选,以对抗pre-let-7miRNA.
- 用顶级SMKI进行分子动力学模拟,以分析结合相互作用.
- 生物物理验证使用微尺度热泳来确认直接结合亲缘关系.
主要成果:
- 确定了几种SMKI,它们对pre-let-7miRNA具有显著的结合亲和力.
- 计算和生物物理方法为SMKI-miRNA复合体形成提供了可靠的数据.
- 该研究证明了使用SMKI来准特定RNA分子的可行性.
结论:
- 经FDA批准的SMKI可以与microRNA结合,这表明基于RNA的治疗机制的潜力.
- 描述SMKI与RNA标相互作用对于理解它们的全部生物和临床影响至关重要.
- 这项工作强调了探索酶抑制剂的转录组标的重要性.
更多相关视频
10:21Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
Published on: February 23, 2024
2.9K
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.4K
相关概念视频
01:22MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
01:16Protein-Drug Binding: Mechanism and Kinetics
994
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
994